Morrow C P, Bundy B N, Hoffman J, Sutton G, Homesley H
Am J Clin Oncol. 1986 Feb;9(1):24-6. doi: 10.1097/00000421-198602000-00007.
Malignant mixed mesodermal tumor (MMMT) of the ovary is a rare, but usually fatal, cancer for which there exists no proven postsurgical therapy. The Gynecologic Oncology Group has evaluated adriamycin in this disease at a dose of 75/m2. Among 10 evaluable cases with measurable disease there was one partial response and no complete responses. Of 21 cases with nonmeasurable tumor four remain clinically free of cancer from 2 to 45 months. There were two treatment-related deaths. We conclude that adriamycin alone as first-line chemotherapy in patients with MMMT of the ovary is not sufficiently active to be clinically useful.
卵巢恶性中胚叶混合瘤（MMMT）是一种罕见但通常致命的癌症，目前尚无经证实的术后治疗方法。妇科肿瘤学组已对阿霉素治疗该病进行了评估，剂量为75/m²。在10例可评估且有可测量病灶的病例中，有1例部分缓解，无完全缓解病例。21例有不可测量肿瘤的病例中，4例在2至45个月内临床无癌。有2例与治疗相关的死亡。我们得出结论，对于卵巢MMMT患者，单独使用阿霉素作为一线化疗的活性不足以在临床上发挥作用。
